PDS Biotechnology
PDSB
54 hedge funds and large institutions have $156M invested in PDS Biotechnology in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 5 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
14% more capital invested
Capital invested by funds: $137M → $156M (+$19.8M)
4% more funds holding
Funds holding: 52 → 54 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.11% less ownership
Funds ownership: 2.58% → 2.47% (-0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$21.1M |
| 2 |
BlackRock
New York
|
+$1.54M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.51M |
| 4 |
State Street
Boston,
Massachusetts
|
+$383K |
| 5 |
Goldman Sachs
New York
|
+$359K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.48M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$569K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$362K |
| 4 |
Millennium Management
New York
|
-$345K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$187K |
PDSB Hedge Fund Activity: Q2 2017 in Review
54 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2017, worth a combined $156M — up 14% from $137M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PDSB positions and 5 closed out — a net gain of 3 holders — while 21 added to existing stakes and 13 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $21.1M. The largest seller was Opaleye Management, cutting an estimated $1.48M.
- 54 institutional investors held PDS Biotechnology (PDSB) as of Q2 2017, up from 52 in Q1 2017.
- Funds reported $156M of PDS Biotechnology stock for Q2 2017, up 14% quarter-over-quarter.
- 8 funds opened new PDS Biotechnology positions in Q2 2017 and 5 closed out, a net change of +3 holders.
- The largest PDS Biotechnology buyer in Q2 2017 was Janus Henderson Group, an estimated $21.1M added.
- The largest PDS Biotechnology seller in Q2 2017 was Opaleye Management, an estimated $1.48M sold.
Based on aggregated 13F filings for Q2 2017.